切换至 "中华医学电子期刊资源库"
高级检索
中华肺部疾病杂志(电子版)

中华肺部疾病杂志(电子版) ›› 2019, Vol. 12 ›› Issue (05) : 544 -549. doi: 10.3877/cma.j.issn.1674-6902.2019.05.002

论著

高原慢性阻塞性肺疾病稳定期血清SP-D水平与肺功能及炎症因子的临床意义
何军頵1, 徐红艳1, 曾以萍1, 邵佳1, 陈杰1, 申永春2, 文富强2,†()   
  1. 1. 610041　成都，西藏自治区人民政府驻成都办事处医院（四川大学华西医院西藏成办分院）　呼吸科
    2. 610041　成都，四川大学华西医院　生物治疗国家重点实验室　呼吸疾病研究室
  • 收稿日期:2019-05-05 出版日期:2019-10-20
  • 通信作者: 文富强
  • 基金资助:
    国家重点研发计划资助项目(No.2016YFC0903600, No.2016YFC1304500)

Clinical significance of serum surfactant protein D level in patients with stable phase of plateau chronic obstructive pulmonary disease and its relationship with pulmonary function and inflammatory factors

Junyun He1, Hongyan Xu1, Yiping Zeng1, Jia Shao1, Jie Cheng1, Yongchun Shen2, Fuqiang Wen2,†()   

  1. 1. Hospital of Chengdu Office of People′s Government of Tibetan Autonomous Region
    2. Department of Medical Informatics, West China Hospital of Sichuan University, Chengdu 610041, China
  • Received:2019-05-05 Published:2019-10-20
  • Corresponding author: Fuqiang Wen
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

何军頵, 徐红艳, 曾以萍, 邵佳, 陈杰, 申永春, 文富强. 高原慢性阻塞性肺疾病稳定期血清SP-D水平与肺功能及炎症因子的临床意义[J]. 中华肺部疾病杂志(电子版), 2019, 12(05): 544-549.

Junyun He, Hongyan Xu, Yiping Zeng, Jia Shao, Jie Cheng, Yongchun Shen, Fuqiang Wen. Clinical significance of serum surfactant protein D level in patients with stable phase of plateau chronic obstructive pulmonary disease and its relationship with pulmonary function and inflammatory factors[J]. Chinese Journal of Lung Diseases(Electronic Edition), 2019, 12(05): 544-549.

目的

探讨高原慢性阻塞性肺疾病(COPD)稳定期患者血清肺泡表面活性蛋白D(SP-D)的水平及与肺功能、炎症因子的临床意义。

方法

收集2016年5月至2017年12月在华西医院就诊的世居高原COPD稳定期的患者150例及健康对照组67例，收集两组的临床资料包括年龄、性别、体质指数(BMI)、吸烟指数及肺功能指标，包括FEV1(第1 s用力呼出气容积)、FEV1%(第1 s用力呼出气容积占预计值百分比)、FEV1/FVC%(第1 s用力呼出气容积/用力肺活量比值)，抽取静脉血测定SP-D、CRP(C反应蛋白)、IL-6(白介素6)、TNF-α(肿瘤坏死因子α)。比较两组之间及COPD稳定期的汉、藏族之间的血清SP-D、CRP、IL-6、TNF-α的浓度差异；并将血清SP-D与COPD稳定期患者的肺功能、全身炎症、CAT(COPD测试评分)、mMRC(改良英国医学研究学会呼吸困难指数)作相关性分析；作SP-D在COPD稳定期的多因素回归分析，并作SP-D在COPD稳定期的ROC分析。

结果

COPD稳定组的SP-D高于对照组[(12 524±8 796)vs.(9 288±5 640 ng/L)，P<0.05]、COPD稳定组的炎症指标如CRP[0.5(2.3)比2(2.5)，P<0.05]、IL-6[2.3(2.2)vs. 1.1(1.4)，P<0.05]、TNF-α[(5.5±2.7)vs.(7.8±6.7)，P<0.05]，均显著高于对照组。COPD稳定组的SP-D与CAT、mMRC评分呈正相关(r＝0.498，P<0.05；r＝0.512，P<0.05)，与炎症因子CRP、IL-6、TNF-α的水平呈正相关(r＝0.369，P<0.05；r＝0.454，P<0.05；r＝0.529，P<0.05)，与肺功能指标FEV1%、FEV1/FVC%呈负相关(r＝-0.404，P<0.05；r＝-0.171，P<0.05)。对COPD稳定期患者，汉、藏族在血清SP-D及炎症因子CRP、IL-6、TNF-α之间的浓度水平均无统计学差异(P>0.05)。对SP-D在COPD稳定期的多因素回归分析，没有发现与稳定期相关的指标，均P>0.05。在ROC统计中，SP-D的阈值为9 303.5，敏感度为0.576，特异度为0.616，SP-D对诊断COPD稳定期有一定诊断价值。

结论

血清SP-D升高可反应全身炎症水平，有助于评估高原COPD患者的肺功能程度及病情变化。对高原COPD病情的预测与评估有一定临床意义。

关键词: 高原, COPD稳定期, 肺泡表面活性蛋白D, 肺功能, 全身炎症反应
Objective

To investigate the serum level of surfactant protein D (SP-D) in the patients with stable phase of plateau chronic obstructive pulmonary disease (COPD) and its relationship with frequent exacerbator phenotype, lung function, and systemic inflammation.

Methods

A total of 150 patients living on plateau for generations with stable COPD hospitalized in West China Hospital of Sichuan University from May 2016 to December 2017 (the COPD group) and 67 healthy controls (the control group) were enrolled in this study. The clinical data of the two groups were collected including their age, gender, body mass index (BMI), the smoking index and the lung function indicators including the forced expiratory volume in one second (FEV1), FEV1%, FEV1/the forced vital capacity (FVC)%. Venous blood was taken to measure the SP-D, C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factorα (TNF-α). The differences in the serum SP-D, CRP, IL-6, and TNF-α were analyzed between the Han and Tibetans in the stable phase of COPD and between the two groups. Correlation analyses were made between the serum SP-D and pulmonary function and systemic inflammation, CAT (COPD testing scores) and modified British Medical Research Council (mMRC) scores in the patients with stable COPD. Statistical multivariate regression analysis was made for the SP-D of the patients in the stable phase of COPD and its relationship with the Han and Tibetans. In ROC analysis, P<0.05 was considered as statistical significance.

Results

The SP-D of the COPD group was higher than that of the control group (12 524±8 796 vs. 9 288±5 640 ng/L, P<0.05), The inflammation indexes, such as CRP [0.5 (2.3) in the COPD group vs. 2 (2.5) in the control group, P<0.05], IL-6 [2.3(2.2) in the COPD group vs. 1.1(1.4) in the control group, P<0.05], and TNF-α(5.5±2.7 in the COPD group vs. 7.8±6.7 in the control group, P<0.05) had significant differences between the two groups. The SP-D of the COPD group was positively correlated with the CAT score (r=0.498, P<0.05), mMRC score (r=0.512, P<0.05), and the levels of inflammatory factors such as CRP (r=0.369, P<0.05), IL-6 (r=0.454, P<0.05) and TNF-α (r=0.529, P<0.05), and negatively correlated with the lung function indexes such as FEV1% (r=-0.404, P<0.05) and FEV1/FVC% (r=-0.171, P<0.05). There was no significant difference in serum SP-D and inflammatory factors of CRP, IL-6 and TNF-α between the Han and Tibetan patients in the stable COPD patients (P>0.05). The multivariate regression analysis showed that P>0.05 was found in the SP-D of the COPD patients, but no indicator related to the stable phase was found. In the ROC statistics, the threshold of SP-D was 9 303.5, the sensitivity was 0.576, and the specificity was 0.616. SP-D had certain diagnostic values for the diagnosis of COPD in the stable phase.

Conclusion

Elevated serum SP-D can reflect the systemic inflammatory levels, is helpful to assess the degree of pulmonary function, and diseases the changes in the patients with high-altitude COPD. It has a certain effect on the prediction and evaluation of plateau COPD.

Key words: Plateau, Chronic obstructive pulmonary disease, Surfactant protein D, Lung functions, Systemic inflammation
表1 COPD患者临床一般资料比较
临床资料 对照组(n＝67) 稳定组(n＝150) P值
年龄(岁，±s) 47.2±12.7 64.3±10.1 <0.001
性别[n(%)] 男 46(68.7) 107(71.3) 0.069
  女 21(31.3) 43(28.7)  
民族[n(%)] 汉 26(38.8) 56(37.3) 0.063
  藏 41(61.2) 94(62.7)  
BMI(kg/m2，±s) 24.6±3.7 23.2±4.2 0.024
吸烟指数(包/年) 380 740 <0.001
平素CAT评分(分，±s) 3.0±1.7 14.6±6.8 <0.001
平素mMRC评分(分，±s) 0.8±0.5 1.3±1.1 0.002
FEV1(L，±s) 2.9±0.8 1.4±0.7 <0.001
FEV1%预计值(%，±s) 99.3±19.1 55.0±21.6 <0.001
FEV1/FVC(%，±s) 85.7±7.0 57.1±17.2 <0.001
TNF-α(ng/L，±s) 5.5±2.7 7.8±6.7 0.018
SP-D(ng/L，±s) 9 288±5 640 12 524±8 796 0.012
CRP(mg/L，M(Q)) 0.5(2.3) 2(2.5) <0.001
IL-6(ng/L，M(Q)) 2.3(2.2) 1.1(1.4) <0.001
图1 COPD患者血清SP-D与FEV1%的关系
图2 COPD患者血清SP-D与CRP的关系
图3 COPD患者血清SP-D与TNF-α的关系
图4 COPD患者血清SP-D与CAT的关系
图5 COPD患者血清SP-D与mMRC的关系
表2 SP-D在COPD稳定期的多因素回归分析
临床资料 β P值
年龄 2.717 0.976
BMI -9.371 0.973
CAT评分 8.610 0.973
mMRC评分 -28.035 0.981
FEV1 8.852 0.994
FEV1% -2.133 0.973
FEV1/FVC -2.316 0.979
CRP -2.379 0.996
IL-6 1.068 0.989
TNF-α -20.321 0.974
SPD -0.001 0.996
表3 SP-D在诊断COPD稳定期的ROC分析结果
面积 标准误 P值 95%CI 阈值 敏感度 特异度 约登指数
0.604 0.040 0.012 0.526～0.681 9 303.500 0.576 0.616 0.193
图6 SP-D诊断COPD稳定期的ROC分析
1
任成山，王关嵩，钱桂生. 慢性阻塞性肺疾病的成因及其治疗的困惑与希望[J/CD]. 中华肺部疾病杂志(电子版), 2019, 12(2): 127-141.
2
Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD executive summary[J]. Am J Respir Crit Care, 2017, 195: 557-582.
3
Wang C, Xu J, Yang L, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health[CPH] study): a national cross-sectional study[J]. Lancet, 2018, 391(10131): 1706-1717.
4
Choudhury G, MacNee W. Role of Inflammation and Oxidative Stress in the Pathology of Ageing in COPD: Potential Therapeutic Interventions[J]. COPD, 2017, 14(1): 122-135.
5
Agustí A, Faner R. Systemic inflammation and comorbidities in chronic obstructive pulmonary disease[J]. Proc Am Thorac Soc, 2012, 9(2): 43-46.
6
陈永新，王晓红，马建林，等. 高原地区老年COPD急性加重期患者血清IL-6及hs-CRP、PA表达及意义[J]. 青海医学院学报，2013, 34(3): 174-176.
7
杨生岳，冯恩志，沈君礼，等. 高原地区慢性阻塞性肺疾病与支气管哮喘患者气道阻塞可逆性对比研究[J]. 西北国防医学杂志，2005, 26(3): 170-172.
8
蒋延文，庞　莉，方秋红，等. 血清炎性因子水平与慢性阻塞性肺疾病继发肺动脉高压的相关性研究[J]. 中华结核和呼吸杂志，2011, 34(12): 904-908.
9
Moreno D, Garcia A, Lema D, et al. Surfactant protein D in chronic obstructive pulmonary disease (COPD)[J]. Recent Pat Endocr Metab Immune Drug Discov, 2014 , 8(1)：42-47.
10
何军頵，蒙　毅，文富强，等. 高原藏族COPD 600例患者合并症的临床分析[J]. 西部医学，2017, 29(1): 32-35.
11
杨荣荣. 藏族人群COPD患病率和危险因素及藏-汉人群的对比研究[D]. 广州：广州医科大学，2013: 1-63.
12
尼玛曲措，何芙蓉，雄　辉，等. 西藏自治区教师吸烟行为及其影响因素的研究[J]. 中国慢性病预防与控制，2010, 18(6): 603-605.
13
文富强，申永春，陈　磊. 肺功能检查在中国慢性阻塞性肺疾病患者中的实践：挑战与对策[J]. 中华结核和呼吸杂志，2017, 40(12): 891-893.
14
Dahl M. Biomarkers for chronic obstructive pulmonary disease: surfactant protein D and C-reactive protein[J]. Am J Resp Crit Care, 2008, 177(11): 1177-1178.
15
Ambade VN, Sontakke AN, Barthwal MS, et al. Diagnostic Utility of Biomarkers in COPD[J]. Respiratory Care, 2015, 60(12): 1729-1742.
16
Celli BR, Locantore N, Yates J, et al. Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease[J]. Am J Resp Crit Care Med, 2012, 185(10): 1065-1072.
17
Garcia-Rio F, Miravitlles M, Soriano JB, et al. Systemic inflammation in chronic obstructive pulmonary disease: a population-based study[J]. Repir Res, 2010, 11: 63.
18
Duvoix A, Miranda E, Perez J, et al. Evaluation of full length, cleaved and nitrosylated serum surfactant ptotein D as biomarkers for COPD[J]. COPD, 2011, 8(2): 79-95.
19
Lomas DA, Silverman EK, Edwards LD, et al. Serum surfactant protein D is steroid sensitive and associated with exacerbations of COPD[J]. Eur Respir J, 2009, 34(1): 95-102.
20
Grek CL, Newton DA, Spyropoulos DD, et al. Hypoxia up-regulates expression of hemoglobin in alveolar epithelial cells [J]. Am J Respir Cell Mol Biol, 2011, 44(4): 439-447.
21
Sims MW, Tal-Singer RM, Kierstein S, et al. Chronic obstructive pulmonary disease and inhaled steroids alter surfactant protein D (SP-D) levels: a cross-sectional study [J]. Respir Res, 2008, 9(1): 13.
22
Shakoori TA, Sin DD, Ghafoor F, et al. Serum surfactant protein D during acute exacerbations of chronic obstructive pulmonary disease[J]. Dis Markers, 2009, 27(6): 287-294.
23
Foreman MG, Kong X, DeMeo DL, et al. Polymorphisms in surfactant protein-D are associated with chronic obstructive pulmonary disease[J]. Am J Respir Cell Mol Biol, 2011, 44(3): 316-322.
24
Gan WQ, Man SF, Sin DD. The interactions between cigarette smoking and reduced lung function on systemic inflammation[J]．Chest, 2005, 127(2): 558-564.
25
Caramori G, Adcock IM, Di Stefano A, et al. Cytokine inhibition in the treatment of COPD[J]. Int J Chron Obstruct Pulmon Dis, 2014, 9: 397-412.
26
Heidari B. The importance of C-reactive protein and other inflammatory markers in patients with chronic obstructive pulmonary disease[J]. Caspian J Intern Med, 2012, 3(2): 428-435.
[1] 杨茂宪, 沈鹏, 王倩倩, 吴旺, 沈永帅, 蒋禛, 徐龙生, 朱建刚, 刘倍倍. 吡啶甲酸镁联合地塞米松对急性呼吸窘迫综合征大鼠的治疗作用研究[J]. 中华危重症医学杂志(电子版), 2024, 17(03): 196-203.
[2] 吴越廷, 周林雨涵, 胡钦, 许华燕, 黄敏, 陈晓勇, 张萌, 李中会, 茹凉, 王秋, 蔡晓唐. 皮质类固醇治疗非卧床杜氏肌营养不良症患儿肺功能与运动功能的纵向研究[J]. 中华妇幼临床医学杂志(电子版), 2024, 20(03): 292-301.
[3] 阙宏亮, 邓君鹏, 李权, 曾腾跃, 沈华, 谢建军. 俯卧位经后腹腔肾上腺腹腔镜手术的研究进展[J]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(02): 188-192.
[4] 张璇, 高杨, 房雅君, 姚艳玲. 保护性机械通气在肺癌胸腔镜肺段切除术中的临床应用[J]. 中华肺部疾病杂志(电子版), 2024, 17(04): 563-567.
[5] 陈冬丽, 邓迎丽, 毕婧. α-干扰素治疗急性呼吸道病毒感染对Th1/Th2平衡及肺功能的影响[J]. 中华肺部疾病杂志(电子版), 2024, 17(04): 590-594.
[6] 王微, 丁霖, 陈茜, 呼延欣, 闫蓓. 综合治疗对慢性阻塞性肺疾病的疗效及转归影响分析[J]. 中华肺部疾病杂志(电子版), 2024, 17(04): 621-624.
[7] 罗孝平, 封敏, 黄川, 唐茜, 蒋艳, 胡莉丽. 渐进式抗阻训练干预在非小细胞肺癌中的临床应用[J]. 中华肺部疾病杂志(电子版), 2024, 17(03): 472-474.
[8] 袁广琴, 朱珠, 林云霞. 胸腺肽联合无创正压通气救治AECOPD并发Ⅱ型呼吸衰竭患者的临床分析[J]. 中华肺部疾病杂志(电子版), 2024, 17(03): 438-441.
[9] 周璇, 谢莉, 邹娟. 尼达尼布对特发性肺纤维化肺功能、肺纤维化程度及PDGF、PGE2、TGF-β1的影响[J]. 中华肺部疾病杂志(电子版), 2024, 17(03): 368-372.
[10] 孙海燕, 周士燕, 张杉杉, 张研, 张茜. 间充质干细胞及其外泌体在高原肺水肿中的潜在治疗机制研究进展[J]. 中华细胞与干细胞杂志(电子版), 2024, 14(03): 186-190.
[11] 梁国豪, 张茜, 张研. 间充质干细胞及其衍生物治疗高原低氧环境下心血管疾病的研究进展[J]. 中华细胞与干细胞杂志(电子版), 2024, 14(02): 107-112.
[12] 陈先志, 许磊, 冯其柱, 王琦. 布地奈德联合复方异丙托溴铵雾化吸入在老年患者腹腔镜围手术期中的应用[J]. 中华肝脏外科手术学电子杂志, 2024, 13(04): 531-536.
[13] 刘娟丽, 马四清, 乌仁塔娜. 髓源性抑制细胞在脓毒症中的研究进展[J]. 中华重症医学电子杂志, 2024, 10(03): 271-278.
[14] 闫维, 张二明, 张克, 安欣华, 向平超. 北京市石景山区40岁及以上居民早期慢性阻塞性肺疾病异质性及影响因素分析[J]. 中华临床医师杂志(电子版), 2024, 18(06): 533-540.
[15] 张克, 张二明, 闫维, 马石头, 安欣华, 包曹歆, 向平超. 北京石景山区40岁以上PRISm和COPD患者的肺功能水平与吸烟情况相关性分析[J]. 中华临床医师杂志(电子版), 2024, 18(02): 122-127.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号